A Study of Apatinib Monotherapy as the Salvage Treatment in Advanced/Recurrent Gynaecological Cancer Patients who Failed from Two or More Lines of Prior Chemotherapy

Trial Profile

A Study of Apatinib Monotherapy as the Salvage Treatment in Advanced/Recurrent Gynaecological Cancer Patients who Failed from Two or More Lines of Prior Chemotherapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Apatinib (Primary)
  • Indications Cervical cancer; Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Jun 2017 New trial record
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top